MBOT Stock — Microbot Medical Inc.

Microbot Medical Inc. (MBOT)

Updated October 16, 2026.

MBOT is a Stock. Total return is -100.0% over the past 34.6 years.

Microbot Medical Inc. is a medical device company developing robotic systems for minimally invasive endovascular and neurovascular surgery, including its LIBERTY endovascular robotic surgical system and NovaCross intraluminal revascularization technology. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to medical device innovation and robotics technology rather than current income.

MBOT performance

Price and return data through 2026-10-16.

Total return is -100.0% over the past 34.6 years. Over the past year its total return — price change plus distributions reinvested — is -66.5%. Its deepest 1-year drawdown was 66.7%.

MBOT key facts

Asset type

Stock

Asset class

Equity

Inception date

03/25/1992

Distribution frequency

None

Last close

$0.95 (as of 2026-10-16)

Market cap

$63,806,561

Average volume

802084.0

Payment date

09/05/2018

Beta

1.046

Payout ratio

0.0%

Forward P/E

31.746

EPS

$-0.25

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MBOT risks and drawbacks

The deepest 1-year drawdown on record here is 66.7%.

Who may consider MBOT — and who may not

It is a weaker fit for investors who need monthly cash flow (MBOT does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on MBOT

• All tickers starting with M

Tagged: Healthcare.

Frequently asked questions